A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.
A Double-dummy, Double-blind, Randomized, Parallel-group, Active Controlled Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Compared to Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.
Sponsor: Novartis Pharmaceuticals
A PHASE3 clinical study on Asthma, this trial is actively recruiting participants. The trial is conducted by Novartis Pharmaceuticals and has accumulated 11 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Feb 2026 — Present [monthly]
Not Yet Recruiting PHASE3
-
Dec 2025 — Feb 2026 [monthly]
Not Yet Recruiting PHASE3
-
Apr 2025 — Dec 2025 [monthly]
Not Yet Recruiting PHASE3
-
Jan 2025 — Apr 2025 [monthly]
Not Yet Recruiting PHASE3
-
Sep 2024 — Jan 2025 [monthly]
Not Yet Recruiting PHASE3
▶ Show 6 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE3
-
Jan 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE3
-
Oct 2023 — Jan 2024 [monthly]
Not Yet Recruiting PHASE3
-
Aug 2023 — Oct 2023 [monthly]
Not Yet Recruiting PHASE3
-
May 2023 — Aug 2023 [monthly]
Not Yet Recruiting PHASE3
-
Apr 2023 — May 2023 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.